People
Dermavant Sciences adds four new members to executive team
18 April 2018 -

Dermavant Sciences, a biopharmaceutical company focused on delivering therapies for dermatologic conditions, has added four new members to its executive team, it was reported yesterday.

David Rubenstein, GlaxoSmithKline's former vice president, discovery and preclinical development, joins the group as its new chief scientific officer. Prior to GSK, he held academic roles at the University of North Carolina. In addition to Rubenstein, Richard Peterson joins the biopharma as its chief financial officer. Peterson, who earlier worked at Sienna Biopharmaceuticals as its chief financial officer, comes to Dermavant Sciences with experience in the dermatology space. He has previously served as chief financial officer for Novan and chief financial officer, executive vice president of Medicis Pharmaceutical Corporation.

Ariel Jasie has been named as the new chief business and strategy officer. Jasie has joined the biopharma from Codiak BioSciences, where he served as chief business officer and prior to that, he served in various executive roles at Celgene, most recently as executive director for strategy and operations. Chris Van Tuyl has joined the company as general counsel. He has earlier served in numerous positions, including corporate secretary, chief compliance officer and associate general counsel at Rayonier, where he oversaw key aspects of the company's spinoff of its chemical business in 2014.

Login
Username:

Password: